Antibiotic therapy for Crohn's disease: A review

Canadian Journal of Gastroenterology

Volumn 20, Issue 10, 2006, Pages 651-655

  Lal, Simon ^a   Steinhart, A Hillary ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antibiotics; Crohn's disease; Inflammatory bowel disease; Perianal Crohn's disease; Postoperative Crohn's disease

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; NITROIMIDAZOLE; PLACEBO; PURINE DERIVATIVE; RIFAMYCIN; RIFAXIMIN; SALAZOSULFAPYRIDINE;

ANTIBIOTIC THERAPY; BIFIDOBACTERIUM; CELLULAR IMMUNITY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; GENETIC SUSCEPTIBILITY; HOST SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; INTESTINE RESECTION; LACTOBACILLUS; MAJOR CLINICAL STUDY; NONHUMAN; PATHOGENESIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; REVIEW;

EID: 33751229883     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/250490     Document Type: Review

References (63)

1. Wild GE. The role of antibiotics in the management of Crohn's disease. Inflamm Bowel Dis 2004;10:321-3.
2. Shanahan F, Bernstein CN. Antibiotics as a first-line therapy for Crohn's disease: Is there any consensus? Inflamm Bowel Dis 2004;10:324-6.
3. Greenberg GR. Antibiotics should be used as first-line therapy for CroWs disease. Inflamm Bowel Dis 2004;10:318-20.
4. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut 2005;54:896-8.
5. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004;53:1-4.
6. Thomas GA, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study. Gut 1998;42:497-500.
7. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-9.
8. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
9. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-7.
10. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31.
11. Veltkamp C, Tonkonogy SL, De Jong YP, et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology 2001;120:900-13.
12. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
13. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094-105.
14. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.
15. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370-6.
16. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
17. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
18. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
19. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-46.
20. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002;37:1034-41.
21. Duchmann R, Kaiser I, Hermann E, Mayer W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
22. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-75.
23. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
24. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
25. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
26. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004;33:335-45.
27. Williams AC, Galley HF, Watt AM, Webster NR. Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 2005;56:502-6.
28. Takahashi HK, Iwagaki H, Xue D, et al. Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-treated monocytes. Antimicrob Agents Chemother 2005;49:3228-33.
29. Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother 2004;16:357-61.
30. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-7.
31. Rosen A, Ursing B, Alm T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology 1982;83:541-9.
32. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-62.
33. Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985;28:81-5.
34. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
35. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1-16.
36. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88:681-4.
37. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
38. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-8.
39. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamin Bowel Dis 2002;8:10-5.
40. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
41. Prantera C, Betio E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: Experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998;30:602-6.
42. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998;12:53-6.
43. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 2002;123:33-40.
44. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000;14:801-6.
45. Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M. Management of inflammatory bowel disease: Does rifaximin offer any promise? Chemotherapy 2005;51 Suppl 1:96-102.
46. Shaffran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005;21:1165-9.
47. Bosworth BP, Scherl E. A novel nonabsorbable antibiotic (rifaximin) in the treatment of moderate to severe Crohn's disease. Gastroenterology 2005;128:576A. (Abst)
48. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
49. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: Endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-5.
50. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol 2003;17:63-73.
51. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
52. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
53. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
54. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30.
55. Schwartz DA, Herdman CR. Review article: The medical treatment of Crohn's perianal fistulas. Aliment Pharmacol Ther 2004;19:953-67.
56. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975;1:775-7.
57. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:599.
58. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982;83:383-7.
59. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40.
60. Solomon M, Mcleod R, O'Conner B, Steinhart AH, Greenberg G, Cohen Z. Combination ciprofloxacin and metronidazole in severe perinanal Crohn's disease. Can J Gastroenterol 1993;7:571-3.
61. Dejaco C, Harter M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W, Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003;18:1113-20.
62. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329-36.
63. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: A pilot study. Dig Dis Sci 2004;49:1280-6.